Onyx Pharmaceuticals upgraded to Buy from Hold at Maxim Maxim upgraded Onyx Pharmaceuticals (ONXX) with a $130 price target citing upside from a potential takeover. Maxim believes Onyx is "seriously interested" in striking a deal at this point and pegs the company's fundamental value at $130-$140 per share. The firm believes Onyx and Amgen (AMGN) are in in the process of price negotiation. Shares of Onyx closed yesterday at $110.99.
News For ONXX From The Last 14 Days
Check below for free stories on ONXX the last two weeks.